Table 5.
Budget impact analysis for the no-test and test (sFlt-1/PlGF) strategies.
| Year | No-test strategy | Test strategy | Total cost for entire cohort (€) | Difference in costs (no-test strategy vs. test strategy; €) | |||
|---|---|---|---|---|---|---|---|
| N | Costs (€) [19] | N | Costs (€) | Test/no-test strategy | No-test strategy | ||
| 1 | 4867 | 53,173,304 | 1217 | 12,874,728 | 66,048,032 | 66,469,362 | –421,330 |
| 2 | 3484 | 38,063,651 | 2600 | 27,505,581 | 63,351,915 | 64,221,605 | –869,690 |
| 3 | 2434 | 26,592,115 | 3650 | 38,613,604 | 60,870,237 | 62,049,860 | –1,179,623 |
| 4 | 1084 | 11,842,996 | 5000 | 52,895,349 | 58,390,277 | 59,951,556 | –1,561,278 |
| 5 | 0 | — | 6084 | 64,363,060 | 56,088,688 | 57,924,209 | –1,835,520 |
| Total within 5 years | 11,869 | 129,672,066 | 18,551 | 196,252,323 | 304,749,152 | 310,616,592 | –5,867,441 |
PlGF: placental growth factor; sFlt-1: soluble fms-like tyrosine kinase-1.